Brief: Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa)
03/04/2025 12:34
April 3 (Reuters) - Incannex Healthcare Inc IXHL.O: INCANNEX HEALTHCARE COMPLETES PHASE 2 ENROLLMENT IN REPOSA PHASE 2/3 TRIAL OF IHL-42X, AN ORAL ONCE-DAILY TREATMENT FOR OBSTRUCTIVE SLEEP APNEA (OSA) Source text: ID:nGNX8DQ7v1 Further company coverage: IXHL.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Incannex Healthcare
See all newsIncannex Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
Incannex Healthcare Inc expected to post a loss of 75 cents a share - Earnings Preview
Brief: Incannex Receives Additional A$5.1 Million Research And Development Tax Incentive Refund
Brief: Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea
Brief: Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position